Homology Medicines Inc
FIXXNASDAQHealthcare·US · USD
$12.36
-0.21 (-1.67%)
Prices as of October 13, 2026 · livePrice
Key statistics
Valuation
Market cap39.92M USD
Enterprise value1.97M USD
Trailing P/E-4.13
Forward P/E-1.34
PEG ratio0.00
Price / sales34.53
Price / book0.00
Profitability
Gross margin0.00%
Operating margin-7967.30%
Profit margin0.00%
Return on assets-133.58%
Return on equity-154.76%
Income (TTM)
Revenue1.16M USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-112.96M USD
Diluted EPS-$1.95
Rev. growth (YoY)0.00%
Balance sheet
Total cash749.00K USD
Total debt1.32M USD
Debt / equity0.02
Current ratio7.25
Book value / share$0.00
Cash flow (TTM)
Operating cash flow-112.37M USD
Levered free cash flow-112.96M USD
Shares & price
Shares outstanding3.23M
Float0.00
Held by institutions0.00%
Beta0.00
50-day MA$12.91
200-day MA$12.91
52-week high$23.57
52-week low$1.91
Dividends
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-041.451.64+13.10%2026-03-173.223.55+10.25%2024-03-12-0.30-0.28+6.67%2023-11-13-0.42-0.57−35.71%
About Homology Medicines Inc
The fund invests at least 80% of its net assets (plus borrowings for investment purposes) in the underlying security and financial instruments with economic characteristics that, in combination, provide 200% leveraged exposure to the price of the underlying security, on a daily basis, consistent with the fund’s investment objective. It is non-diversified.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Albert Seymour Ph.D.
- Employees
- 7
- Headquarters
- Bedford, MA, United States
- Website
- www.homologymedicines.com